ReviewWorld journal of gastroenterology2016
Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Trial
- Hepatocellular carcinoma risk stratification to identify patients suitable for intensive surveillance in viral hepatitis: the SELECT score.European radiology · 2026Article
- Metabolic dysfunction-associated fatty liver disease in chronic hepatitis B: dual effects on hepatocarcinogenesis and evolving strategies for risk prediction.Frontiers in immunology · 2026Review
- Clinical Characteristics of Hepatitis B Virus-Associated Hepatocellular Carcinoma Patients in Southwest Nigeria.Pathogens (Basel, Switzerland) · 2025Article
- VALIDATION OF THE PAGE-B SCORE AS A PROGNOSIS OF DEVELOPMENT TO HEPATOCELLULAR CARCINOMA (HCC) IN CHRONIC HEPATITIS B, IN THE BRAZILIAN POPULATION.Arquivos de gastroenterologia · 2025Observational
- 48-week prognostic analysis of very low-level viremia in patients with hepatitis B cirrhosis: a single-center retrospective study.Frontiers in medicine · 2025Article
- Article
- Article
- Evaluation of PAGE-B Score for Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients: Reliability, Validity, and Responsiveness.Biomedicines · 2024Review
- Love-hate relationship between hepatitis B virus and type 2 diabetes: a Mendelian randomization study.Frontiers in microbiology · 2024Article
- Probability analysis of hepatocellular carcinoma in hepatitis patients in the gray zone.Frontiers in medicine · 2024Article
- A hierarchical multilabel graph attention network method to predict the deterioration paths of chronic hepatitis B patients.Journal of the American Medical Informatics Association : JAMIA · 2023Article
- Transcriptomic Analysis of Hepatitis B Infected Liver for Prediction of Hepatocellular Carcinoma.Biology · 2023Article
- Lenvatinib plus sintilimab with or without transarterial chemoembolization for intermediate or advanced stage hepatocellular carcinoma: a propensity score-matching cohort study.American journal of cancer research · 2023Article
- Development of a nomogram to predict the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis on antivirals.Frontiers in oncology · 2023Article
- Comment on the risk of hepatocellular carcinoma with chronic hepatitis B infection in Sweden.Hepatology communications · 2022Article
- What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association.JHEP reports : innovation in hepatology · 2022Review
- A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook.Nature reviews. Gastroenterology & hepatology · 2022Review
- A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study.BMC cancer · 2022Article
- Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.Journal of hepatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B virus (HBV) infection is a major cause of cirrhosis and hepatocellular carcinoma (HCC). Applying the same strategies for antiviral therapy and HCC surveillance to all chronic hepatitis B (CHB) patients would be a burden worldwide. To properly manage CHB patients, it is necessary to identify and classify the risk for HCC development in such patients. Several HCC risk scores based on risk factors such as cirrhosis, age, male gender, and high viral load have been used, and have negative predictive values of ≥ 95%. Most of these have been derived from, and internally validated in, treatment-naïve Asian CHB patients. Herein, we summarized various HCC prediction models, including IPM (Individual Prediction Model), CU-HCC (Chinese University-HCC), GAG-HCC (Guide with Age, Gender, HBV DNA, Core Promoter Mutations and Cirrhosis-HCC), NGM-HCC (Nomogram-HCC), REACH-B (Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B), and Page-B score. To develop a noninvasive test of liver fibrosis, we also introduced a new scoring system that uses liver stiffness values from transient elastography, including an LSM (Liver Stiffness Measurement)-based model, LSM-HCC, and mREACH-B (modified REACH-B).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.